A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

If you or a loved one has lung cancer, you may be looking into different treatment options. One new medicine you may hear about is Ensacove (ensartinib). In December 2024, the FDA approved Ensacove as ...

SYDNEY, Feb. 4 (Xinhua) -- Scientists in Australia have mapped the "neighborhoods" of lung cancer cells and found that cell metabolism plays a key role in determining how patients respond to ...

Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer. Data are n (%). This is an ASCO Meeting ...

Study Highlights the Efficacy of PMC in Suppressing Non-Small Cell Lung Cancer Growth SEOUL, SOUTH KOREA, January 23, 2026 /EINPresswire.com/ — A South Korean research team has found that ...

Patients with advanced lung cancer who received immunochemotherapy before 15:00 (3 p.m.) had a more delayed disease ...

Amtagvi monotherapy achieved a 25.6% objective response rate and 71.8% disease control rate in NSCLC patients without actionable mutations. The median duration of response was not reached after 25.4 ...

Research reveals the efficacy of cancer therapies and organ transplant treatments may improve by synchronizing with the ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...